WEBULL
WebtradeDownload

How Thyroid Center Partnership At Pulse Biosciences (PLSE) Has Changed Its Investment Story

Simply Wall St · 1d ago
  • Pulse Biosciences announced a partnership with the Clayman Thyroid Center in Tampa for commercial use of the nPulse Vybrance Percutaneous Electrode System and joint data collection on nsPFA treatment of benign thyroid nodules.
  • The Clayman Thyroid Center is now the sole provider of nPulse technology for symptomatic benign thyroid nodules in the Tampa Bay area, which gives Pulse Biosciences a focused setting to test real world procedure flow, resource use, and patient demand.
  • We will now look at how Pulse Biosciences’ investment narrative could be shaped by this real world nsPFA thyroid data partnership.
Spot emerging medtech momentum beyond Pulse Biosciences by scanning our hand picked 34 healthcare AI stocks, which are pushing new treatment tools and procedures into real clinics.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences, you need to believe its nanosecond PFA platform can move from limited launch to routine use in thyroid and cardiac procedures. The key near term swing factor is whether early Vybrance thyroid users keep adopting and repeating cases. The Clayman Thyroid Center deal adds a focused test bed but does not remove execution risk.

The biggest near term risk is the gap between high operating costs and very modest revenue, alongside a rich P/B multiple versus peers. If procedure volumes, reimbursement progress, or new hospital sites do not build fast enough, sustained losses and potential future dilution stay front of mind for shareholders.

The Clayman Thyroid Center partnership is the announcement that directly ties into these catalysts. It moves Vybrance from concept into paid use at a high volume endocrine surgery hub while also collecting outcomes data. That combination gives you a live view of real world procedure flow, consumable pull through, and patient interest.

For a high valuation, low revenue medtech like Pulse Biosciences, this kind of controlled market development matters. If the site can produce robust data and repeat usage patterns, it may support future reimbursement discussions and guideline efforts. If results or throughput disappoint, it would reinforce concerns about adoption speed and cash burn.

What The Current Pulse Biosciences Forecasts Assume

Analyst models around Pulse Biosciences lean heavily on what thyroid and cardiac penetration could look like several years from now rather than what the income statement shows today. Forecasts bake in very rapid top line expansion and a big shift in profitability even though the business is currently running at a sizeable loss.

Consensus expectations point to revenue growth of 218.5% per year over the next three years, which implies a very large compounding effect on sales if that pace holds. At the same time, projections assume profit margins move from a loss position of 6,755.8% to a positive margin of 12.6%, roughly in line with the broader US medical equipment peer group.

Those margin assumptions translate into forecast earnings of US$4.8 million by 2029 and a move in earnings per share to US$0.06. Today the company reports a loss of US$80.1 million, so analyst numbers imply an earnings swing of roughly US$85 million to reach the 2029 profit goal.

Revenue expectations are explicit as well. To match the current analyst fair value work, Pulse Biosciences would need to reach US$38.3 million of sales in 2029 while generating that US$4.8 million profit. The forecast period used to anchor these estimates is the 2029 financial year.

Valuation work in the consensus report scales those earnings into a future P/E multiple. To line up with the US$62.33 analyst price target, the stock would need to trade on a P/E of 1,337.3x in 2029 based on the US$4.8 million earnings estimate, compared with a current P/E of 41.3x on today’s loss profile. That multiple is far above the 24.7x currently quoted for the US medical equipment industry.

Share count is not assumed to stand still either. Analysts are building in 5.25% annual growth in shares outstanding over the next three years, which would dilute each slice of future earnings if the profit pool does not expand at least as quickly as the share base.

Pulse Biosciences' narrative projects US$38.3 million revenue and US$4.8 million earnings by 2029. This requires 218.5% yearly revenue growth and an earnings increase of roughly US$85 million from a loss of US$80.1 million today.

Discover how Pulse Biosciences' fair value indicates an 18% potential upside to its current price that may not last much longer.

NasdaqCM:PLSE 1-Year Stock Price Chart
NasdaqCM:PLSE 1-Year Stock Price Chart

Exploring Other Perspectives

Not every analyst treats the Clayman Thyroid Center partnership as a game changer for Pulse Biosciences. The most cautious group already assumed only 25.3% annual revenue growth and just US$2.3 million of sales with US$293.2 thousand of earnings by 2029. That much lower bar may shift once real thyroid data from Tampa filters through, so treat these viewpoints as a spectrum to explore rather than a script to follow.

Explore another Pulse Biosciences fair value estimate, including one that suggests as much as 69% downside from the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider doing your own research and going with your instincts.

Looking For More Ideas Beyond Pulse Biosciences?

If the Pulse Biosciences story has sharpened your thinking about risk, reward and valuation, it can help to line it up against other opportunities that match different goals and comfort levels. The Simply Wall St Screener gives you a way to filter for traits that matter to you, rather than relying on headlines or hype.

Here are a few focused starting points you can use right now: